DelveInsight’s, “Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2022,” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Cytidine Deaminase Inhibitors (CDA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cytidine Deaminase Inhibitors (CDA): Overview
Cytidine deaminase inhibitors are molecules that inhibit the activity of the enzyme cytidine deaminase. Cytidine deaminase is an evolutionarily conserved enzyme of the pyrimidine salvage pathway. It catalyzes the hydrolytic deamination of cytidine and deoxycytidine to form uridine and deoxyuridine, respectively. Human cytidine deaminase (CDA) is an enzyme prominent for its role in catalyzing metabolic processing of nucleoside-type anticancer and antiviral agents. It is thus a promising target for the development of small molecule therapeutic adjuvants. Cytidine deaminase inhibitors are considered as a potential and promising treatment for tumors with highly expressed CDA.
The companies and academics are working to assess challenges and seek opportunities that could influence Cytidine Deaminase Inhibitors (CDA) R&D. The therapies under development are focused on novel approaches for Cytidine Deaminase Inhibitors (CDA).
This segment of the Cytidine Deaminase Inhibitors (CDA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cytidine Deaminase Inhibitors (CDA) Emerging Drugs
ASTX727: Astex Pharmaceuticals
ASTX727 is a novel, orally administered fixed dose combination of cedazuridine, an inhibitor of cytidine deaminase, with the anti-cancer DNA hypomethylating agent, decitabine. By inhibiting cytidine deaminase, cedazuridine inhibits the major mechanism by which decitabine is degraded in the gut and liver, and the combination therefore permits the efficient delivery of decitabine orally.
Further product details are provided in the report……..
This segment of the report provides insights about the different Cytidine Deaminase Inhibitors (CDA) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 2+ key companies which are developing the Cytidine Deaminase Inhibitors (CDA). The companies which have their Cytidine Deaminase Inhibitors (CDA) drug candidates in the most advanced stage, i.e. Phase III include, Astex Pharmaceuticals.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Cytidine Deaminase Inhibitors (CDA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytidine Deaminase Inhibitors (CDA) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytidine Deaminase Inhibitors (CDA) drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Cytidine Deaminase Inhibitors (CDA): Overview
Pipeline Therapeutics
Therapeutic Assessment
Cytidine Deaminase Inhibitors (CDA) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cytidine Deaminase Inhibitors (CDA) Collaboration Deals
Late Stage Products (Registered)
ASTX727: Astex Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug name: Company name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ASTX-030: Astex Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Cytidine Deaminase Inhibitors (CDA) Key Companies
Cytidine Deaminase Inhibitors (CDA) Key Products
Cytidine Deaminase Inhibitors (CDA)- Unmet Needs
Cytidine Deaminase Inhibitors (CDA)- Market Drivers and Barriers
Cytidine Deaminase Inhibitors (CDA)- Future Perspectives and Conclusion
Cytidine Deaminase Inhibitors (CDA) Analyst Views
Cytidine Deaminase Inhibitors (CDA) Key Companies
Appendix
List of Table
Table 1: Total Products for Cytidine Deaminase Inhibitors (CDA)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Cytidine Deaminase Inhibitors (CDA)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Astex Pharmaceuticals
• Novo Nordisk
